ARA-290 vs Trofinetide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cibinetide, ARA 290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Also: Daybue, Daybue Stix
Trofinetide is a synthetic version of a tiny three-amino-acid fragment (glycine-proline-glutamate) that the body clips off IGF-1. It is the first drug ever approved for Rett syndrome: the FDA approved it as Daybue in March 2023 for patients 2 years and older, Health Canada followed in October 2024, and the EU authorised it as Daybu in August 2026 after first refusing it. It is a real, approved medicine with a real but modest effect, and the trade-off is blunt: most patients get diarrhea, and a meaningful share stop because of it.
Key Comparison Insights
- Trofinetide is FDA approved, while ARA-290 remains in research stages.
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
- Trofinetide has stronger research evidence (FDA Approved) compared to ARA-290 (Phase II/III Trials).
Detailed Comparison
| Attribute | ARA-290 | Trofinetide |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | EPO does two jobs - it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job. It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO's clotting and cardiovascular risks. Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect. | Rett syndrome is usually caused by loss-of-function mutations in the MECP2 gene, which disrupts how neurons mature and connect. Trofinetide is an analog of GPE, the N-terminal tripeptide of IGF-1, built to survive longer in the body than the natural fragment. In Mecp2-deficient mice, GPE partially reversed Rett-like symptoms, and the working theory is that trofinetide supports synaptic function and dampens neuroinflammation. The honest part: the FDA label states that the mechanism by which trofinetide works in Rett syndrome is unknown. It is taken by mouth in large gram-level doses, has an elimination half-life of about 1.5 hours, and is cleared mainly by the kidneys, which is why it is not recommended in moderate or severe kidney impairment. |
| Common Dosing | 4 mg daily Once daily | 5-12 g twice daily, set by body weight (labeled dose) Twice daily, morning and evening |
| Administration | Subcutaneous injection | Oral solution (200 mg/mL) by mouth or via gastrostomy tube; also available as a powder (Daybue Stix) mixed into liquid |
| Typical Duration | 28-day courses in trials | Ongoing for the approved indication; dose is interrupted, reduced, or stopped for severe diarrhea, dehydration, or significant weight loss |
| Best Time to Take | Consistent daily timing | Morning and evening, as prescribed |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ARA-290 has more real human data than most peptides in this category. A 2015 phase 2 trial published in Molecular Medicine (Brines et al., registered as NTR3858) found that ARA-290 improved hemoglobin A1c and lipid profile and significantly improved PainDetect neuropathic symptom scores in type 2 diabetes patients, with increased corneal nerve fiber density in those with small fiber neuropathy. In sarcoidosis-associated small fiber neuropathy, controlled studies reported increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers, though in at least one dose-ranging trial pain did not clearly separate from placebo - an honest caveat worth keeping. Tolerability in these small, early-phase studies has been favorable, with no signal of EPO-style blood thickening. That said, the trials are small and early, ARA-290 holds FDA orphan drug status for sarcoidosis neuropathy but is not approved, and the program stalled around 2020. Net: real clinical evidence pointing in a hopeful direction, but not yet proven enough to be a standard treatment. | Approval rests on one pivotal trial, LAVENDER (Neul and colleagues, Nature Medicine 2023): 187 girls and young women aged 5 to 20 with Rett syndrome, randomized to trofinetide or placebo for 12 weeks. Both co-primary endpoints were hit. The caregiver-rated Rett Syndrome Behaviour Questionnaire improved by 4.9 points versus 1.7 on placebo, and the clinician-rated CGI-I score was 3.5 versus 3.8, with effect sizes in the small-to-moderate range (Cohen's d 0.37 and 0.47). A communication measure also favored the drug. The price was tolerability: diarrhea hit about 81% on trofinetide versus 19% on placebo, vomiting 27% versus 10%, and 17% dropped out for side effects (mostly diarrhea). The label adds that 12% lost more than 7% of body weight. Open-label extensions (LILAC and the 32-month LILAC-2, published in Med in 2024) reported continued improvement, but without a placebo arm those data cannot prove the drug caused it. In December 2025 the FDA approved Daybue Stix, a powder version, based on a bioequivalence study. In Europe, the EMA's committee first refused the application in February 2026, then recommended approval on re-examination in June 2026 for patients 5 and older, noting the improvements were small but relevant for a serious disease and that the trial showed no effect on seizures. Bottom line: a genuine first treatment for a disease that had none, with modest benefit and a heavy GI cost. |
Frequently Asked Questions: ARA-290 vs Trofinetide
What is the difference between ARA-290 and Trofinetide?
ARA-290 is a cognitive peptide that ara-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (epo), engineered to calm inflammation and repair nerves without thickening the blood the way epo does. it has been tested in real phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds fda orphan drug status, but it was never approved and development largely stalled. so: genuine clinical data, promising signals, no finish line. Trofinetide is a cognitive peptide that trofinetide is a synthetic version of a tiny three-amino-acid fragment (glycine-proline-glutamate) that the body clips off igf-1. it is the first drug ever approved for rett syndrome: the fda approved it as daybue in march 2023 for patients 2 years and older, health canada followed in october 2024, and the eu authorised it as daybu in august 2026 after first refusing it. it is a real, approved medicine with a real but modest effect, and the trade-off is blunt: most patients get diarrhea, and a meaningful share stop because of it. The main differences lie in their mechanisms of action and clinical applications.
Which is better, ARA-290 or Trofinetide?
Neither is universally "better" - the choice depends on your specific goals. ARA-290 is typically used for cognitive purposes, while Trofinetide is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can ARA-290 and Trofinetide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using ARA-290 and Trofinetide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.